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Sunday, February 26, 2012 157aFurthermore, the presence of any of the three HCMmutations slowed the kinet-
ics of Ca2þ-dissociation induced structural changes in both cTnI(Ir)- and
cTnI(Rr)-cTnC interactions, but to a different extent. These results suggest
that different HCM mutations and PKC phosphorylation of cTnI may have
unique structural and kinetic effects on cTnI(Ir)- and cTnI(Rr)-cTnC interac-
tions that collectively effect pathophysiology and functional modulation, re-
spectively. Structural effects of the PKC pseudo-phosphorylation mutants
and HCM mutants, as well as overall effects when PKC pseudo-
phosphorylation and HCM mutations are combined into one mutant, on both
cTnI(Ir)- and cTnI(Rr)-cTnC interactions will be also discussed.
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The contraction of cardiac muscles is powered by actin-activated myosin mo-
tor, a process regulated by calcium through the troponin complex. The troponin
complex consists of three protein subunits, troponin C (TnC), troponin T (TnT)
and troponin I (TnI). TnI is the inhibitory subunit of troponin and plays an es-
sential role in regulating the actomyosin ATPase cycle.
Cardiac TnI (cTnI) has a unique N-terminal extension that contains protein ki-
nase A phosphorylation sites Ser23 and Ser24. Mimicking the effect of PKA
phosphorylation, a restrictive proteolysis of the N-terminal extension of cTnI
(cTnI-ND) occurs during cardiac adaptation to decrease myofilament calcium
sensitivity and increase the rate of myocardial relaxation. To understand the
mechanism of the cTnI N-terminal regulation, we applied stopped-flow fluor-
ometry to measure each step of the ATPase cycle and the mant-dATP binding
rates in cardiac myofibrils isolated from double transgenic mouse hearts ex-
pressing solely cTnI-ND with a knockout of the endogenous cTnI gene and
wild type controls. The mant-dATP binding rate of the cTnI-ND myofibrils
(3.88/s/mM) was three time faster than that of wild-type control (0.97/s/mM).
Km (mant-dATP) of cTnI-ND myofibrils (10 mM) is significantly higher than
that of wild type myofibrils (139 mM). These results indicate that ATP binds
to myosin at a significantly higher rate in cTnI-ND cardiac muscle. Further ex-
periments are underway to measure the ADP dissociation rate, phosphate dis-
sociation rate, and binding/dissociation rate of the myosin motor domain to
actin filaments. (Supported by grants from the National Institutes of Health
and an Incubator Grant from the Office of Vice President Research of Wayne
State University).
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The cardiac TnT deletion (HcTnT-DE96) linked to Restrictive Cardiomyopa-
thy (RCM) dramatically increases the Ca2þ sensitivity of force development
in skinned fibers (J. Biol. Chem. 283(4):2156–66). This study explores whether
HcTnT-DE96 interferes with convergent regulation by Protein Kinase A (PKA)
which decreases myofilament Ca2þ sensitivity. Native cTnT of porcine cardiac
skinned fibers was displaced by HcTnT-WT or HcTnT-DE96 and reconstituted
with binary complex containing pseudo non-phosphorylatable cTnI (cTnI-SS/
AA.cTnC) or pseudo-phosphorylated (cTnI-SS/DD.cTnC). For comparison,
skinned fibers were also reconstituted with binary cTnI.cTnC phosphorylated
by PKA in vitro (cTnI-2P.cTnC) to assess effects of HcTnT-DE96 on Ca2þ sen-
sitivity of force development. As expected, fibers displaced with HcTnT-WT
reconstituted with cTnI-SS/DD.cTnC decreased Ca2þ sensitivity of force com-
pared to control reconstituted with cTnI-SS/AA.cTnC. In contrast, fibers dis-
placed with HCTnT-DE96 and reconstituted with cTnI-SS/DD.cTnC or cTnI-
SS/AA.cTnC had similar Ca2þ sensitivities. When fibers were displaced with
HcTnT3-WT or HcTnT3-DE96 and reconstituted with cTnI-2P.cTnC, the ex-
pected decrease in Ca2þ sensitivity was observed for both. These results sug-
gest that phosphorylation mimetic cTnI-SS/DD may not always mimic
phosphorylation by PKA. Furthermore, the mutant HcTnT-DE96 protein re-
vealed reduced a-helical content by CD spectroscopy when compared to
WT. Thermo-denaturation studies indicated that the mutant protein unfolded
earlier thanWT and was partially unfolded at physiological temperatures. Fluo-
rescence studies containing CTnC-IAANS demonstrated that a high order of
complexity (thin filament þ myosin S1) is needed to better approach changes
in Ca2þ affinity produced by the RCM cTnT mutation in skinned fibers. The
effects of the HcTnT mutation on Ca2þ sensitivity properties were likely dueto altered interactions of TnT with other thin filament proteins. Supported
AHA 09POST2300030 (MSP), NIH R01-HL42325 (JDP) and J&E King
1KN13-34001 (JRP).
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Previously, we reported the generation and characterization of an R21C cardiac
troponin I (cTnI) knock-in (KI) mouse model linked to hypertrophic cardiomy-
opathy in humans (Biophys JVol 98, Issue 3, Suppl 1, 148a). TheR21Cþ/þ (ho-
mozygote) mice displayed decreased cTnI phosphorylation at serines23/24,
decreased Ca2þ sensitivity response (rightward shift) of the myofilament upon
PKA incubation and marked late stage heart hypertrophy (R 12 months of
age). Here, we further investigated effects of the cTnI R21C mutation on intra-
cellular Ca2þ ([Ca2þ]i) and contractility in R21Cþ/þ cardiomyocytes before
and after 100 nmol/L isoproterenol (ISO) treatment. Incubationwith ISO slightly
reduced diastolic [Ca2þ]i in R21Cþ/þ cardiomyocytes, consistent with in-
creased resting sarcomere length (SL) (relaxation), however diastolic [Ca2þ]i in-
creased in WT cardiomyocytes without altering resting SL. Despite similar SL
shortening between both strains at baseline or after ISO, WT had a strong re-
sponse to ISO with increased DCa2þ amplitude (systolic [Ca2þ]i - diastolic
[Ca2þ]i) but no significant increase in R21Cþ/þ throughout a range of frequen-
cies was observed. Ca2þ decay was similar between strains before or after ISO,
however SL relaxation in R21Cþ/þ was slower but with stronger response to
ISO compared to WT. Furthermore, the rate of relaxation of R21Cþ/þ skinned
fibers was measured by flashphotolysis prior to and after PKA incubation. Data
was fit with a double exponential and major changes were identified in the first
rate constant (k1). After PKA incubation, k1 in WT skinned fibers significantly
increased (19.02/sec to 28.49/sec). In comparison, k1 inR21Cþ/þ skinned fibers
increased from (22.66/sec to 26.40/sec) before and after PKA treatment. These
data taken together demonstrates that the HCM R21C-cTnI mutation increases
intracellular calcium buffering and delays sarcomere relaxation without chang-
ing Ca2þ decay. Supported by NIH R01-HL432325 (JDP).
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Background
The Frank-Starling mechanism describes the intrinsic relationship between
ventricular filling (end-diastolic volume) and contraction (stroke volume) and
is based on length-dependent activation of cardiac sarcomeres. An increase
in sarcomere length with increased end-diastolic volume increases myofilament
Ca2þ-sensitivity and thereby contractility. In the present study we investigated
if length-dependent activation is altered in human hypertrophic cardiomyopa-
thy (HCM) with known mutations in thin filament proteins.
Methods
Comparisons were made between cardiac samples from a patient harboring
a homozygous TNNT2 (troponin T) mutation, a patient carrying a heterozygous
TPM1 (tropomyosin) mutation, two patients harboring a heterozygous TNNI3
(troponin I) mutation and non-failing donors. Force measurements were per-
formed in single Triton-permeabilized cardiomyocytes at various [Ca2þ] and
sarcomere lengths of 1.8 and 2.2 mm, with and without protein kinase A
(PKA)-pretreatment.
Results
Myofilament Ca2þ-sensitivity at 2.2 mm did not significantly differ between
TNNT2, TPM1 and TNNI3 (EC50 = 2.5150.10, 2.1650.19 and 2.6950.16
mmol/L, respectively), while it was significantly higher compared to donors
(EC50 = 3.0950.09 mmol/L).
The length-dependent increase in myofilament Ca2þ-sensitivity was not signif-
icantly different between TNNT2, TPM1 and TNNI3 (DEC50 = 0.4150.17,
0.2950.13 and 0.2950.15 mmol/L, respectively), but significantly reduced
compared to donors (DEC50 = 0.7650.06 mmol/L).
158a Sunday, February 26, 2012PKA-treatment did not alter myofilament Ca2þ-sensitivity in the TNNT2 and
TPM1 samples, whereas Ca2þ-sensitivity was significantly reduced in the
TNNI3 to values observed in donor.
PKA-pretreatment did not restore the reduced length-dependent activation of
HCM-groups.
Conclusions
Perturbed length-dependent activation may represent a feature of HCM and
contribute to impaired cardiac function in HCM-patients. Our data show that
responsiveness to b-adrenergic receptor stimulation mimicked by PKA-
treatment is absent in a HCM-homozygous TNNT2 mutation. Although hearts
with a mutation in TPM1 and TNNI3 responded to PKA, evident from a reduc-
tion in myofilament Ca2þ-sensitivity, the blunted length-dependent activation
was not corrected by PKA.
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Protein kinase A (PKA)-mediated phosphorylation of contractile proteins upon
activation of b-adrenergic receptors decreases myofilament Ca2þ-sensitivity
and accelerates relaxation of the heart. Phosphorylation of the PKA sites
(Ser23/24) of cardiac troponin I (cTnI) is decreased in end-stage failing com-
pared to non-failing human hearts. However, the site-specific functional conse-
quences of phosphorylation at these sites in human myocardium are unknown.
Therefore, we studied the effect of phosphorylation of cTnI-Ser23/24 on myo-
filament function in explanted human heart tissue.
Myofilament force development was measured at various [Ca2þ] in permeabi-
lized cardiomyocytes in which endogenous troponin complex was partially ex-
changed (6952%) with recombinant (Myc-tag labeled) whole human troponin
complexes (1 mg/ml). Site-directed mutations were used to mimic phosphory-
lation of both Ser23 and Ser24 (cTnI-DD), Ser24 only (cTnI-AD), Ser23 only
(cTnI-DA) or dephosphorylation of both sites (cTnI-AA).
In donor cardiomyocytes,myofilament Ca2þ-sensitivity (pCa50) was signifi-
cantly reduced in cTnI-DD (pCa50=5.3950.01) compared to cTnI-AA
(pCa50=5.5050.01), cTnI-AD (pCa50=5.4850.01) and cTnI-DA
(pCa50=5.5150.01). The maximal rate of tension redevelopment (ktr) was de-
creased by 15.1-19.8% in cTnI-AD compared to cTnI-AA, cTnI-DA and cTnI-
DD. Pseudo-phosphorylation of Ser23/24 had no effect on maximal or passive
force nor on the steepness of the force-pCa relation. In end-stage failing cardi-
omyocytes, using cTnI-DD concentrations between 0 and 1 mg/ml in order to
vary the degree of exchange, a linear decline in the pCa50 vs cTnI-DD content
by 0.1350.03 units was observed, saturating at 5257% of cTnI-DD.
Our data indicate that (1) pseudo-phosphorylation of both PKA-sites on cTnI is
required to reduce myofilament Ca2þ-sensitivity, (2) pseudo-phosphorylation
of Ser24 on cTnI results in a slowing of crossbridge kinetics and (3) the max-
imal reduction in pCa50 is reached at ~50% bis-phosphorylated cTnI.
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Background: One of the mutated sarcomeric proteins in familial hypertrophic
cardiomyopathy (FHC) is Troponin I (cTnI), a down-stream target of the b-ad-
renergic receptor pathway. Activation of this pathway leads to protein kinase A
(PKA)-mediated phosphorylation of cTnI and sarcomere desensitization to
Ca2þ to improve muscle relaxation. Moreover, cTnI phosphorylation was
shown to enhance sarcomere length-dependent activation (i.e. Frank-Starling
mechanism). We investigated if the responsiveness to PKA and to an increase
in sarcomere length is impaired by mutant cTnI in human FHC.
Methods: A comparison was made between cardiac samples from two FHC pa-
tients harboring the R145W mutation in the TNNI3 gene (TNNI3mut) and non-
failing donor hearts. Isometric force was measured in Triton-permeabilized
cardiomyocytes at different [Ca2þ] and sarcomere lengths of 1.8 and 2.2 mm
before and after treatment with exogenous PKA.Results: At a sarcomere length of 2.2 mm, TNNI3mut cells (n=30) showed lower
maximal force (26.354.9 kN/m2) and similar passive force (2.150.2 kN/m2)
compared to donor cells (n=48; 36.452.3 and 2.450.3 kN/m2, respectively).
In addition, a significantly higher Ca2þ-sensitivity (EC50)(2.6950.16 mM) and
a decreased steepness (2.1750.10) of the force-Ca2þ relation were found in
TNNI3mut compared to donor (3.0950.09 mM and 3.7550.12, respectively).
The increase in Ca2þ-sensitivity (i.e. length-dependent activation; DEC50)
upon an increase in sarcomere length was significantly smaller in TNNI3mut
(0.2950.15) compared to donor (0.7650.06) cells. Treatment with PKA de-
creased myofilament Ca2þ-sensitivity in TNNI3mut to values observed in donor,
but did not correct the reduced length-dependent activation.
Conclusions: Our data show preserved responsiveness to PKA in FHC harbor-
ing the R145Wmutation, but a blunted length-dependent activation, which was
not corrected by PKA. Reduced maximal force and perturbed Frank-Starling
mechanism, both at baseline and after PKA, may impair contractile perfor-
mance in human FHC with mutant cTnI.
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We are investigating the mechanism by which the Myosin Light Chain Kinase-
Calmodulin (MLCK-CaM) complex phosphorylates Smooth Muscle Myosin
(SMM). MLCK-CaM phosphorylation of SMM is the primary regulator of
smooth muscle contraction, and is required for the catalytic activity of the
myosin motor. We have previously shown that MLCK-CaM-SMM forms
a tightly-associated complex and that MLCK-CaM co-purifies with SMM.
This co-purified MLCK-CaM can phosphorylate SMM which was shown by
actin filament motility in an in vitro motility assay. In addition, using total in-
ternal reflectance fluorescence (TIRF) microscopy, we were able to character-
ize dynamic interactions of MLCKwith monomeric SMM using QuantumDots
(QD) to label MLCK.
The goal of our current study is to determine how a small amount of MLCK is
capable of phosphorylating a much larger amount of SMM. The ratio of MLCK
to SMM in smooth muscle cells is approximately 1:70, yet the MLCK is able to
produce contractions in the cell within seconds. To answer this question, we are
investigating the interaction of MLCK-QD with reconstituted SMM filaments.
This approach is moving more towards the in vivo conditions, and will help us
answer the long term question of how MLCK is phosphorylating SMM within
smooth muscle cells.
We have to reconstituted SMM filaments which are identical in structure to
native SMM filaments, and are capable of being phosphorylated by MLCK.
Our reconstituted filaments are fluorescently labeled and are lightly cross-
linked, which allows them to be stable in the presence of ATP and/or high ionic
strength. We have shown that QD-MLCK co-localizes with our reconstituted
SMM filaments. Our data proposes a mechanism of SMM phosphorylation
by the physical movement of MLCK along a contractile fiber within the smooth
muscle cell.
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Human ventricular cardiac myosin regulatory light chain (MYL2) phosphory-
lation modifies Ser15. This modification affects MYL2 secondary structure and
modulates the Ca2þ sensitivity of contraction in cardiac tissue. Smooth muscle
myosin light chain kinase (smMLCK) is prevalent in uterus and present in other
contracting tissues including cardiac muscle. The recombinant 130 kDa (short)
smMLCK phosphorylated Ser15 in MYL2 in vitro. Specific modification of
Ser15 was verified by direct detection of the phospho group on Ser15 with
mass spectrometry. SmMLCK also specifically phosphorylated myosin regula-
tory light chain Ser15 in porcine ventricular myosin and chicken gizzard
smooth muscle myosin (Ser20 in smooth muscle) but failed to phosphorylate
the myosin regulatory light chain in rabbit skeletal myosin. Michaelis-
Menten Vm and KM constants for Ser15 phosphorylation in MYL2, porcine
ventricular myosin, and chicken gizzard myosin are similar. These data demon-
strate that smMLCK is a specific and efficient kinase for the in vitro phosphor-
ylation of MYL2, cardiac, and smooth muscle myosin. Whether smMLCK
plays a role in cardiac muscle regulation or response to a disease causing stim-
ulus is unclear but it should be considered a potentially significant kinase in car-
diac tissue on the basis of its specificity, kinetics, and tissue expression.
Supported by NIH NIAMS and NHLBI grants R01AR049277 and
R01HL095572.
